Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Citi Opens Upside Catalyst Watch on Alnylam Pharmaceuticals (ALNY)
September 20, 2022 5:38 AM EDTCiti analyst David Lebowitz reiterated a Buy rating and $280.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)
Opens Upside Catalyst WatchFor an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $216.00 yesterday.
... More